Research programme: respiratory tract disorder therapeutics - Zai Lab

Next Previous
Drug Profile

Research programme: respiratory tract disorder therapeutics - Zai Lab

Alternative Names: ZL 2101

Latest Information Update: 19 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Developer ZAI Lab
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis

Most Recent Events

  • 12 Aug 2014 Two undisclosed respiratory tract disorder therapeutics licensed to Zai Lab worldwide
  • 12 Aug 2014 Preclinical trials in Chronic obstructive pulmonary disease in China (unspecified route)
  • 12 Aug 2014 Preclinical trials in Idiopathic pulmonary fibrosis in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top